The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Stepping Up The Fight Against Severe Malaria In Zambia: An Innovative Approach Scales Up 25/04/2019 David Branigan As leaders from across the globe met in Paris today to renew commitments against malaria on World Malaria Day, a Geneva-based group announced the scale-up of a project in rural Zambia that reduced severe malaria fatality by 96 percent. The innovative project administers life-saving drugs to children with malaria in rural communities, and provides immediate […] Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Stepping Up The Fight Against Severe Malaria In Zambia: An Innovative Approach Scales Up 25/04/2019 David Branigan As leaders from across the globe met in Paris today to renew commitments against malaria on World Malaria Day, a Geneva-based group announced the scale-up of a project in rural Zambia that reduced severe malaria fatality by 96 percent. The innovative project administers life-saving drugs to children with malaria in rural communities, and provides immediate […] Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
MMV: Zambia Pilot Project Reduces Malaria Mortality By 96 Percent 03/09/2018 David Branigan A new pilot project conducted in a remote region of Zambia, MAMaZ Against Malaria, has demonstrated that with the right combination of access to medicines, trained community healthcare workers and rapid response rural transportation systems, malaria mortality in rural areas can be prevented, according to the project partnership. Continue reading -> Posts navigation Newer posts